Want to join the conversation?
$ABBV said it launched VENCLEXTA early in 2Q16 in its initial indication for relapsed/refractory CLL patients with a 17p deletion, which represents a smaller addressable patient population in the US. The company has begun a measured commercial rollout to ensure adequate physician training and expects a modest level of VENCLEXTA sales for 2016.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!